Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer.
about
Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancerAbiraterone in the treatment of metastatic castration-resistant prostate cancerTargeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening.Tumour biomarkers: homeostasis as a novel prognostic indicatorPeptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancerAurora Kinase A Promotes AR Degradation via the E3 Ligase CHIP.HE3235 inhibits growth of castration-resistant prostate cancer.Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacityThe androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens.Transcription factor and microRNA regulation in androgen-dependent and -independent prostate cancer cells.Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.Mutation of the androgen receptor causes oncogenic transformation of the prostateElevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotypeOncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferon-dependent antiviral defense.PSA Decrease with Fulvestrant Acetate in a Hormone-Resistant Metastatic Prostate Cancer Patient: A Case ReportSex steroid metabolism in benign and malignant intact prostate biopsies: individual profiling of prostate intracrinologyAdjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 studyInhibition of androstenediol-dependent LNCaP tumour growth by 17alpha-ethynyl-5alpha-androstane-3alpha, 17beta-diol (HE3235)Androgen receptor signaling in prostate cancer development and progression.Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells.Hormones and prostate carcinogenesis: Androgens and estrogens.The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptorCorepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells.Identification of novel androgen receptor target genes in prostate cancer.Antioxidants Abrogate Alpha-Tocopherylquinone-Mediated Down-Regulation of the Androgen Receptor in Androgen-Responsive Prostate Cancer Cells.Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome.Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression.Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer.Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapyPotent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.Expression of androgen receptor splice variants in clinical breast cancers.Natural disordered sequences in the amino terminal domain of nuclear receptors: lessons from the androgen and glucocorticoid receptors.Genomic biomarkers, androgen pathway and prostate cancer.Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target.Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.Targeting the androgen receptor pathway in prostate cancer.Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate CancerExperimental evidence of persistent androgen-receptor-dependency in castration-resistant prostate cancer.
P2860
Q26773634-3AA966E4-6AD3-45D1-8A51-9C047F5C38E8Q26853635-E8E94494-4668-4AC9-AC14-3CE4423CDD33Q27675350-123B8218-EDAE-4A17-988A-DF66D70E4A0CQ28069898-08589461-03C6-43F7-9B66-19F8249BCF03Q28291526-AECFB1DC-F2E0-4119-915E-0A7DF9A572B9Q30252352-54A4ADCE-8627-47DE-960D-522EA137021AQ30491204-750F30E4-AD3D-48A9-AB10-62F4D954118FQ30853584-1ED19F07-896F-411B-ABAC-A0BEC3D414D8Q33316388-F159781D-5158-4F9F-8CC7-91F802C82B95Q33373567-75BABF3A-1B1E-4EB5-ADF2-0220DAEDB890Q33566395-B92A2185-608E-4076-B109-FA8BCB53FA44Q33732154-53D3A06A-33D4-4581-A99F-A72C69C581F3Q33733903-7FFC18A7-2047-4847-B43F-FAFD6EE3EBB8Q33806399-7EEBA722-6A89-411E-83AD-2761030A197BQ34054729-0E19716A-E11C-4516-AAFF-AD27393DB8EDQ34092890-E59FE2E5-B919-40B5-AEE7-3AB2BA6414C1Q34179268-FDFB712A-45F6-45E3-8C6F-4E183E451E34Q34972660-904253FF-242B-4E9C-B49D-C1629A3C6310Q35183663-B1777D4B-915C-4639-9A5D-66C9E51A7455Q35372023-695EEB14-B87F-4882-874C-945399DEA6DFQ35687198-F54BA067-DF1C-454E-B51D-74A5206C114DQ35838409-67F57FDF-ACB0-4187-8298-E574A47AAACBQ35858203-49C418A4-7AFA-4C0F-8008-B5E27DD0713BQ35865261-8043EA2A-63D9-4D0F-A43E-14951340DC86Q35961226-D8C41EF8-2485-4CA1-A231-0FBCB6962F14Q36113793-8C9F6A1E-A5E6-4830-836A-4CD882898A2DQ36140754-6D97348F-07E0-443A-BFA4-449BC7C6C8E0Q36238784-B01C1586-17AF-4760-B482-1C1B0AACEA4AQ36298863-4D973F35-9E42-4997-9ED9-49EAF0C19290Q36381291-78ADFED4-8C60-48A4-A53D-5CA3E1D4720CQ36387830-B71F0B35-9D80-4BBA-B03B-A18AF391477CQ36642876-B8614852-65FF-45E4-8DB4-A2CA432DAC8BQ36689084-227E7730-CE5E-425D-AD37-7E8E01096A0FQ36803788-A5786A89-88E5-4651-866B-1FDC2AFB3770Q36845131-A3BC6441-2DFA-47B5-A3E5-73B3B8ED079CQ36849142-2EF09727-FD76-4792-BB4D-97F2BE953781Q36937170-94E4ABD2-0980-44A9-B66C-0321DB6567D7Q36953028-FBCF41F2-737F-45C5-92C5-540D2583097DQ37009071-A8A984CB-E171-4BE7-B29F-3F1EA1ACF3C8Q37139070-F372903D-7D59-4423-A347-303720C9FA13
P2860
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Targeting the androgen recepto ...... ion-resistant prostate cancer.
@ast
Targeting the androgen recepto ...... ion-resistant prostate cancer.
@en
type
label
Targeting the androgen recepto ...... ion-resistant prostate cancer.
@ast
Targeting the androgen recepto ...... ion-resistant prostate cancer.
@en
prefLabel
Targeting the androgen recepto ...... ion-resistant prostate cancer.
@ast
Targeting the androgen recepto ...... ion-resistant prostate cancer.
@en
P2093
P356
P1476
Targeting the androgen recepto ...... ion-resistant prostate cancer.
@en
P2093
Grant Buchanan
Howard I Scher
Lisa M Butler
Wayne D Tilley
William Gerald
P304
P356
10.1677/ERC.1.00525
P577
2004-09-01T00:00:00Z